These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36650613)

  • 41. Prevention of syncytial respiratory virus infection with palivizumab: descriptive and comparative analysis after 12 years of use.
    Narbona-Lopez E; Uberos J; Checa-Ros A; Rodriguez-Belmonte R; Muñoz-Hoyos A
    Minerva Pediatr; 2018 Dec; 70(6):513-518. PubMed ID: 27598776
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
    Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
    J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.
    Rodriguez WJ; Gruber WC; Welliver RC; Groothuis JR; Simoes EA; Meissner HC; Hemming VG; Hall CB; Lepow ML; Rosas AJ; Robertsen C; Kramer AA
    Pediatrics; 1997 Mar; 99(3):454-61. PubMed ID: 9041304
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders.
    Paes B; Kim D; Saleem M; Wong S; Mitchell I; Lanctot KL;
    Eur J Pediatr; 2019 Mar; 178(3):377-385. PubMed ID: 30610419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.
    Feltes TF; Sondheimer HM; Tulloh RM; Harris BS; Jensen KM; Losonsky GA; Griffin MP;
    Pediatr Res; 2011 Aug; 70(2):186-91. PubMed ID: 21522037
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CHD and respiratory syncytial virus: global expert exchange recommendations.
    Tulloh RMR; Medrano-Lopez C; Checchia PA; Stapper C; Sumitomo N; Gorenflo M; Jung Bae E; Juanico A; Gil-Jaurena JM; Wu MH; Farha T; Dodge-Khatami A; Tsang R; Notario G; Wegzyn C
    Cardiol Young; 2017 Oct; 27(8):1504-1521. PubMed ID: 28619123
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Variation in Inhaled Medication Use for Infants With Congenital Heart Disease and Bronchiolitis.
    Ahuja N; Richardson T; Brady P; Foster BA; Godown J; Lu E; Madsen N; Shah SS; Wagner T; Wu S; Russell C;
    Hosp Pediatr; 2023 Aug; 13(8):710-717. PubMed ID: 37403632
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [ISRCTN46561076].
    Langley JM; Smith MB; LeBlanc JC; Joudrey H; Ojah CR; Pianosi P
    BMC Pediatr; 2005 May; 5(1):7. PubMed ID: 15876347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of congenital heart disease on outcomes among pediatric patients hospitalized for influenza infection.
    Ghimire LV; Chou FS; Moon-Grady AJ
    BMC Pediatr; 2020 Sep; 20(1):450. PubMed ID: 32988364
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A regional cohort study of the treatment of critically ill children with bronchiolitis.
    Carroll CL; Faustino EV; Pinto MG; Sala KA; Canarie MF; Li S; Giuliano JS; The Northeast Pediatric Critical Care Research Consortium
    J Asthma; 2016 Dec; 53(10):1006-11. PubMed ID: 27177013
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada.
    Mitchell I; Li A; Bjornson CL; Lanctot KL; Paes BA;
    Am J Perinatol; 2022 Nov; 39(15):1668-1677. PubMed ID: 33657636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015).
    Li A; Wang DY; Lanctôt KL; Mitchell I; Paes BA;
    Pediatr Infect Dis J; 2017 May; 36(5):445-450. PubMed ID: 28403044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hospitalizations for viral respiratory infections in children under 2 years of age: epidemiology and in-hospital complications.
    Zurita-Cruz JN; Gutierrez-Gonzalez A; Manuel-Apolinar L; Fernández-Gárate JE; Arellano-Flores ML; Correa Gonzalez RA; Vázquez-Rosales G; Sanchez-Armas R; Cisneros-González N
    BMC Pediatr; 2020 Jun; 20(1):285. PubMed ID: 32517775
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Respiratory Syncytial Virus is the Most Common Causative Agent of Viral Bronchiolitis in Young Children: An Updated Review.
    Hon KL; Leung AKC; Wong AHC; Dudi A; Leung KKY
    Curr Pediatr Rev; 2023; 19(2):139-149. PubMed ID: 35950255
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry.
    Cohen SA; Zanni R; Cohen A; Harrington M; VanVeldhuisen P; Boron ML;
    Pediatr Cardiol; 2008 Mar; 29(2):382-7. PubMed ID: 17926087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low age, low birthweight and congenital heart disease are risk factors for intensive care in infants with bronchiolitis.
    Mecklin M; Heikkilä P; Korppi M
    Acta Paediatr; 2017 Dec; 106(12):2004-2010. PubMed ID: 28799175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
    Manzoni P; Paes B; Lanctôt KL; Dall'Agnola A; Mitchell I; Calabrese S; Maule M; Girardi E; Harimoto T; Li A
    Pediatr Infect Dis J; 2017 Jan; 36(1):2-8. PubMed ID: 27649365
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
    Kua KP; Lee SWH
    Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monoclonal Antibody Treatment of RSV Bronchiolitis in Young Infants: A Randomized Trial.
    Alansari K; Toaimah FH; Almatar DH; El Tatawy LA; Davidson BL; Qusad MIM
    Pediatrics; 2019 Mar; 143(3):. PubMed ID: 30760509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acute Lower Respiratory Infections Associated With Respiratory Syncytial Virus in Children With Underlying Congenital Heart Disease: Systematic Review and Meta-analysis.
    Chaw PS; Wong SWL; Cunningham S; Campbell H; Mikolajczyk R; Nair H;
    J Infect Dis; 2020 Oct; 222(Suppl 7):S613-S619. PubMed ID: 31599958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.